On February 10, 2020, the White House released the Administration’s budget proposal for Fiscal Year (FY) 2021, A Budget For America’s Future. This document summarizes the President’s recommendations for funding…
On January 28, 2020, HRSA posted results of its 340B Program audit of four pharmaceutical manufacturers in fiscal year 2019. Three of the four audited manufacturers were found to have…
On January 27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight by the Department of Health and Human Services (HHS) of the 340B duplicate…
On January 17, 2020, the Medicare Payment Advisory Commission (MedPAC) held its first meeting of the year, including a session discussing a report requested by the House Energy and Commerce…
On January 8, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an Informational Bulletin (Bulletin) outlining CMS’s view of current “best practices” by states to avoid 340B duplicate…
The federal appeals court for the District of Columbia Circuit recently ruled in favor of the Humana Medicare Advantage plan in a case by a 340B covered entity contending that…
Last week, Apexus published a tool which states for the first time HRSA’s policy that all non-FQHC federal grantees are required to register each of their off-site locations as separate…
Earlier this month, the Alliance for Integrity and Reform of 340B (“AIR340B”), a national advocacy group funded largely by pharmaceutical companies, released an update to their previous reports on charity…
On October 9, 2019, the White House issued two executive orders with potential implications on HRSA’s ability to enforce its sub-regulatory guidance, including its patient definition, against covered entities. In…
340B Health reports that Capt. Krista Pedley, the Director of OPA, stated last week at the Medicaid Drug Rebate Conference that OPA is reevaluating its enforcement of 340B program guidance…